Lifeward Ltd.

https://www.golifeward.com

Lifeward Ltd. is a medical device company that designs, develops, and commercializes solutions for physical rehabilitation and recovery, focusing on enhancing mobility and wellness for individuals with physical and neurological conditions. The company's mission is to relentlessly drive innovation to transform the lives of individuals with physical limitations or disabilities, empowering them to pursue their ambitions. Lifeward is headquartered in Yokneam Illit, Israel, with significant operations in Marlborough, Massachusetts, USA, and Berlin, Germany.

Lifeward's product portfolio includes the ReWalk Personal Exoskeleton, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. These technologies provide gait training and mobility assistance for a range of conditions, including spinal cord injury, stroke, multiple sclerosis, brain injury, and orthopedic/sports medicine rehabilitation. The company supports both clinical settings and home/community use, offering comprehensive customer support and technical service for its products.

In recent developments, Lifeward successfully closed a strategic partnership with Oramed in March 2026, acquiring Oramed's Protein Oral Delivery (POD™) technology and securing up to $47 million in funding to diversify its biomedical innovation efforts. Mark Grant assumed the role of President and CEO in June 2025. The company also achieved CE Mark approval for its ReWalk 7 Personal Exoskeleton in September 2025 and expanded Medicare Advantage coverage for the ReWalk Personal Exoskeleton to include major insurers like Aetna, Humana, and United Healthcare in February 2026. Lifeward continues to expand its offerings, including the acquisition of AI-enabled upper body exoskeleton technology for stroke survivors in February 2026, solidifying its position as a global leader in rehabilitation technology.

Latest updates

Lifeward Acquires Oramed Tech, Injects $47M in Capital

Event summary

  • Lifeward has acquired Oramed’s Protein Oral Delivery (POD™) technology.
  • The partnership provides Lifeward with access to up to $47 million in capital, receiving an initial $10 million on March 25, 2026.
  • Lifeward has made changes to its board of directors as part of the transaction.
  • The deal is positioned by Lifeward as a path to profitability and expansion into a large biotech market.

The big picture

Lifeward’s acquisition of Oramed’s POD™ technology represents a significant shift towards diversifying its biomedical innovation pipeline beyond its core rehabilitation technology offerings. The $47 million capital injection provides a short-term boost, but the long-term success depends on the technology’s clinical validation and integration into Lifeward’s existing business model. This move signals a desire to compete in a larger, more lucrative biotech market, but also introduces new execution risks.

What we're watching

Integration Risk
The success of this partnership hinges on Lifeward’s ability to effectively integrate Oramed’s POD™ technology into its existing product portfolio and operations, which could be complicated by differing corporate cultures and development timelines.
Capital Deployment
How Lifeward allocates the $47 million in capital will be a key indicator of the partnership’s strategic value; a focus on R&D versus marketing could signal different growth priorities.
Clinical Validation
The market’s reaction to clinical data generated using the POD™ technology will be crucial in determining the long-term value of the acquisition and its impact on Lifeward’s overall valuation.

Lifeward Acquires Exoskeleton Tech, Secures Oramed Partnership for Pipeline Funding

Event summary

  • Lifeward received shareholder approval for a strategic investment and technology collaboration agreement with Oramed Pharmaceuticals, acquiring Oramed’s Protein Oral Delivery (POD™) technology platform.
  • Lifeward has agreed to acquire a powered upper-body exoskeleton technology with integrated AI capabilities, complementing its ReWalk platform.
  • Lifeward achieved expanded reimbursement coverage for its ReWalk Personal Exoskeleton with Aetna, Humana, and UnitedHealthcare, covering approximately 16 million lives.
  • Lifeward reported revenue of $5.1 million for Q4 2025, a 33% decrease year-over-year, and $22.0 million for the full year 2025, a 14% decrease year-over-year.

The big picture

Lifeward's strategic shift towards a diversified biomedical innovation company, fueled by the Oramed partnership and exoskeleton acquisition, represents a significant bet on expanding beyond its core neuro-rehabilitation business. This move aims to address the growing demand for advanced medical technologies and secure a more sustainable revenue stream, but carries the risk of diluting focus and complicating operations. The company's ability to effectively manage these new assets and navigate the regulatory landscape will be key to its long-term success.

What we're watching

Regulatory Headwinds
The success of the Oramed partnership hinges on the approval and subsequent commercialization of oral biologic therapies, which faces inherent regulatory and clinical trial risks.
Execution Risk
Lifeward’s ability to integrate the acquired exoskeleton technology and achieve projected gross margins will be critical to demonstrating the success of its diversified strategy.
Market Adoption
The pace at which the expanded reimbursement coverage translates into increased adoption of the ReWalk Personal Exoskeleton will determine the effectiveness of this strategic initiative.

Lifeward Secures Shareholder Nod for Oramed Partnership, Eyes Biotech Expansion

Event summary

  • Lifeward shareholders approved the issuance of shares related to a strategic partnership with Oramed Pharmaceuticals.
  • The partnership integrates Oramed’s POD™ oral delivery technology into Lifeward’s portfolio.
  • Oramed will fund the clinical development of the POD™ platform and acquire a significant equity stake in Lifeward.
  • The deal provides Lifeward with potential access to up to $47 million in capital.
  • The transaction is expected to close following satisfaction of customary closing conditions.

The big picture

Lifeward’s move to incorporate Oramed’s oral drug delivery technology represents a strategic shift towards a diversified biomedical portfolio, moving beyond its core neuro-rehabilitation business. This partnership, structured with Oramed funding clinical development, reflects a common trend of smaller biotech firms leveraging larger MedTech platforms for growth and access to capital. The deal’s success will depend on Lifeward’s ability to effectively manage the integration and capitalize on the substantial market opportunity within oral drug delivery, particularly in diabetes.

What we're watching

Integration Risk
The success of this partnership hinges on the effective integration of Oramed’s POD™ technology into Lifeward’s existing MedTech business, which could present operational and cultural challenges.
Clinical Trial Success
The clinical development of the POD™ platform, particularly ORMD-0801, is critical for realizing the partnership’s potential; setbacks in clinical trials could significantly impact Lifeward’s valuation.
Capital Deployment
How Lifeward utilizes the $47 million in potential capital will be key; selective investment in complementary technologies, as stated, needs to demonstrate a clear return on investment to justify the partnership's structure.

Lifeward Regains Nasdaq Compliance After Price Dip

Event summary

  • Lifeward Ltd. has regained compliance with Nasdaq’s minimum bid price requirement.
  • The company’s stock price maintained a closing bid of $1.00 or more for 10 consecutive business days, ending March 9, 2026.
  • The Nasdaq Listing Qualifications Staff has closed the prior bid price deficiency matter.
  • Lifeward designs and commercializes medical technology for physical rehabilitation and recovery, including ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit.

The big picture

Lifeward's recent Nasdaq compliance issue highlights the vulnerability of smaller-cap medical device companies to market volatility and investor sentiment. While regaining compliance removes an immediate threat of delisting, the underlying factors that contributed to the price decline – likely a combination of growth concerns and broader market conditions – remain relevant. The company's ability to demonstrate consistent revenue growth and profitability will be crucial for maintaining investor confidence and avoiding similar situations in the future.

What we're watching

Financial Stability
The company's ability to sustain this compliance level will depend on continued operational performance and investor sentiment, as a return to sub-$1 pricing could trigger renewed delisting concerns.
Growth Trajectory
How Lifeward’s core product adoption rates, particularly for newer offerings like the ReStore Exo-Suit, will influence its stock price and overall financial health remains a key indicator.
Regulatory Landscape
Changes in reimbursement policies from CMS and other payers could significantly impact Lifeward’s revenue and, consequently, its stock valuation.

Lifeward Partners with AbilityLab to Streamline Exoskeleton Access

Event summary

  • Lifeward is collaborating with Shirley Ryan AbilityLab to offer dedicated clinic days for evaluation and trial of the ReWalk Personal Exoskeleton, starting in Q2 2026.
  • The clinics aim to accelerate adoption of the ReWalk exoskeleton for individuals with spinal cord injury (SCI).
  • Shirley Ryan AbilityLab will provide clinical evaluation, training, and support throughout the process.
  • This marks Lifeward’s first collaboration with a nationally recognized rehabilitation research hospital.

The big picture

Lifeward's collaboration with Shirley Ryan AbilityLab represents a strategic shift towards integrating its exoskeleton technology within established clinical workflows. This move addresses a key barrier to adoption – the complexity of evaluation and fitting – and positions Lifeward to capitalize on the growing demand for assistive robotics in rehabilitation. The partnership also highlights the increasing importance of specialized clinics in driving adoption of complex medical devices, a trend likely to accelerate as the market matures.

What we're watching

Adoption Rate
The success of this collaboration hinges on Lifeward's ability to convert evaluations into sales; a significant drop-off between trial and purchase would signal underlying issues with product suitability or pricing.
Reimbursement
Third-party payor coverage, particularly from CMS, remains a critical factor for widespread adoption; any changes in reimbursement policies could significantly impact Lifeward's revenue projections.
Competitive Landscape
The partnership may attract other exoskeleton manufacturers to seek similar collaborations, intensifying competition and potentially impacting Lifeward's market share and pricing power.

Lifeward Acquires AI-Powered Exoskeleton Tech to Expand Neuro-Rehab Portfolio

Event summary

  • Lifeward Ltd. is acquiring technology assets and know-how from Skelable Ltd., including functional prototypes of a robotic upper body orthotic device with AI capabilities.
  • The total consideration for the acquisition is $480,000, comprised of Lifeward equity and a nominal cash payment.
  • A key engineering team from Skelable Ltd., with over 60 years of combined experience, will join Lifeward.
  • Lifeward anticipates the new upper body exoskeleton will be ready for commercial launch within 18-24 months, following development and regulatory approvals.

The big picture

Lifeward's acquisition of Skelable’s technology represents a strategic move to expand its neuro-rehabilitation portfolio beyond lower-limb solutions, directly addressing a significant underserved market of stroke survivors. This $480,000 deal, while relatively small, signals Lifeward's commitment to building a comprehensive, whole-body rehabilitation platform and leveraging synergies across its product lines. The acquisition also highlights the growing trend of robotics and AI integration within the medical device industry, particularly for assistive technologies.

What we're watching

Integration Risk
The success of this acquisition hinges on the effective integration of Skelable’s engineering team and technology into Lifeward’s existing development framework; any friction could delay commercialization and impact projected timelines.
Reimbursement
While Lifeward anticipates leveraging existing CMS pathways, securing favorable reimbursement rates for the new upper-body exoskeleton will be crucial for widespread adoption and profitability.
Market Adoption
The pace at which clinicians and patients adopt this new upper-limb orthotic, compared to existing therapies, will determine the ultimate commercial success and impact on Lifeward’s revenue projections.

Lifeward Executes 1-for-12 Reverse Share Split to Meet Nasdaq Listing Standards

Event summary

  • Lifeward Ltd. (LFWD) will implement a 1-for-12 reverse share split effective February 24, 2026.
  • Shareholders authorized the reverse split and related amendments to the Articles of Association on January 6, 2026.
  • The company will increase its authorized share capital to 100,000,000 shares.
  • The reverse split aims to increase the per-share price above the Nasdaq minimum $1.00 threshold.
  • Approximately 18.3 million pre-split shares will be reduced to roughly 1.5 million post-split shares.

The big picture

Lifeward's reverse share split is a direct response to falling share prices, indicating challenges in meeting Nasdaq’s listing requirements. This action, while intended to boost the share price, is often viewed negatively by investors as a sign of underlying financial weakness. The move highlights the increasing scrutiny faced by smaller-cap medical technology companies navigating regulatory hurdles and market volatility.

What we're watching

Listing Stability
Whether the reverse split will sustainably restore Lifeward’s compliance with Nasdaq listing requirements, or if further corrective actions will be needed.
Investor Sentiment
How the market perceives the reverse split, as it can signal underlying financial distress and potentially impact investor confidence.
Capital Needs
The pace at which Lifeward can generate sufficient revenue to support its operations and potentially avoid future need for additional capital raises.

ReWalk Exoskeleton Gains Broader Coverage from Medicare Advantage Insurers

Event summary

  • Aetna has authorized Medicare Advantage coverage for ReWalk Personal Exoskeleton beneficiaries, joining Humana and UnitedHealthcare.
  • The three insurers collectively represent approximately 16 million Medicare Advantage beneficiaries in the United States.
  • This coverage expansion recognizes the ReWalk exoskeleton as medically necessary for individuals with spinal cord injury.
  • A beneficiary, a nurse with thoracic spinal cord injury, has received approval for the device through her Aetna Advantage plan.

The big picture

This coverage expansion represents a significant step for Lifeward, potentially unlocking a substantial market opportunity within the Medicare Advantage population. While the 16 million beneficiary figure is large, securing consistent medical necessity determinations from major insurers demonstrates a shift towards recognizing exoskeleton technology as a viable therapeutic intervention. The company's ability to navigate the complex reimbursement landscape and demonstrate long-term value will be critical for sustained growth.

What we're watching

Adoption Rate
The pace of beneficiary enrollment under these new coverage authorizations will be a key indicator of ReWalk's market penetration within the Medicare Advantage segment.
Competitive Landscape
Further expansion of coverage by other major Medicare Advantage insurers could signal broader industry acceptance of exoskeleton-assisted rehabilitation and intensify competition.
Clinical Data
Continued generation of robust clinical data supporting the efficacy and cost-effectiveness of the ReWalk system will be crucial to sustaining and expanding payer coverage.

Lifeward Acquires Oramed Tech, Secures $47M Investment for Biotech Pivot

Event summary

  • Lifeward is acquiring Oramed’s Protein Oral Delivery (POD™) technology, targeting the injectable drugs market.
  • Oramed is taking a 49.99% equity stake in Lifeward, receiving up to $47 million in investment through equity and convertible notes.
  • The transaction includes a clinical trial management agreement where Oramed will fund and manage clinical trials for POD™.
  • Lifeward CEO Mark Grant, previously at Medtronic and Bristol Myers Squibb, is leading the company’s diversification strategy.
  • The deal is contingent on shareholder approval and standard closing conditions.

The big picture

Lifeward’s acquisition of Oramed’s POD™ technology represents a significant strategic shift, moving the company from a pure-play MedTech provider into a diversified biomedical platform. This move aims to capitalize on the $600+ billion injectable drug delivery market, but carries inherent risks associated with biotech development and regulatory hurdles. The $47 million investment provides a runway, but the company’s ability to generate returns from its existing product lines will be crucial for sustaining this expansion.

What we're watching

Execution Risk
Lifeward’s ability to successfully integrate Oramed’s technology and manage clinical trials will be critical to realizing the potential upside, given Oramed’s prior Phase 3 trial failure.
Regulatory Approval
The success of the POD™ platform hinges on securing regulatory approval, a process that could be lengthy and uncertain, potentially impacting the timeline for commercialization.
Financial Stability
Whether Lifeward can achieve sustainable profitability from its existing MedTech products to support the ongoing investment in the biotech portfolio remains a key factor for long-term success.

Lifeward Appoints Lantheus CFO as Chairman Amidst Executive Transition

Event summary

  • Bob Marshall, CFO and Treasurer of Lantheus Holdings, has been appointed Chairman of the Board of Lifeward, effective January 1, 2026.
  • Joseph Turk is stepping down from the Board to become Chief Executive Officer of Care Enablement at Fresenius Medical Care.
  • Marshall has served on Lifeward’s Board and chaired its Audit Committee since 2024.
  • Marshall previously held leadership roles at Zimmer Biomet Holdings, including Vice President, Investor Relations and Corporate Treasurer.

The big picture

The appointment of Bob Marshall, a finance executive from a radiopharmaceutical company, suggests Lifeward is prioritizing financial discipline and operational efficiency as it expands its product portfolio and market reach. Joseph Turk’s departure to Fresenius Medical Care indicates a potential broadening of his professional focus within the broader healthcare landscape. This transition occurs as Lifeward, a ~$1.5B market cap company, seeks to solidify its position as a leader in assistive medical technology.

What we're watching

Governance Dynamics
Marshall’s appointment, while internal, signals a potential shift in strategic oversight as Lifeward navigates a period of growth and regulatory scrutiny within the medical device sector.
Financial Performance
Given Marshall’s background in financial leadership, investors should monitor whether his focus leads to demonstrable improvements in Lifeward’s profitability and capital allocation strategies.
Regulatory Headwinds
The company's ability to secure and maintain regulatory approvals, particularly for its exoskeleton technology, will remain a critical factor impacting its growth trajectory and Marshall’s influence on that process.
CID: 561